The U.S. Nuclear Medicine Market was valued at USD 7.8 billion in 2024 and is estimated to grow at a CAGR of 14.4% to reach USD 30.7 billion by 2034.
The robust growth is fueled by the rise of radiopharmaceutical innovations, increased incidence of chronic diseases, expanding use of personalized treatments, and supportive reimbursement frameworks. Nuclear medicine, a highly specialized area of medical imaging and therapy, utilizes radiopharmaceuticals to both diagnose and treat medical conditions. Unlike traditional imaging methods, nuclear techniques offer deeper molecular and functional insight into tissues and organs. As the healthcare industry moves toward precision care, nuclear imaging is gaining prominence for its ability to deliver accurate diagnostics and targeted therapies. The sector is also being shaped by technological breakthroughs, the surge of oncology theranostics, rising investment in drug development, and an expanding network of diagnostic facilities. Theranostics is accelerating adoption in cancer care by combining imaging and therapeutic solutions into one approach. This enables real-time tracking of targeted radiopharmaceuticals, improving therapeutic precision and minimizing adverse effects, especially in oncology cases.
The diagnostics segment held a 66.5% share in 2024, due to growing demand for early-stage disease detection. The rising burden of cancer, heart disease, and neurological disorders is prompting widespread use of imaging platforms like PET and SPECT. These technologies provide accurate and early detection of illness, allowing for more effective and personalized treatment plans. Their ability to identify disease before structural changes occur is driving broader clinical acceptance.
The cardiology segment is projected to register a CAGR of 14.6% through 2034. This growth is backed by the rising number of patients with cardiovascular conditions and the need for accurate diagnostic procedures. Nuclear imaging modalities are proving critical in evaluating cardiac health, guiding physicians with detailed functional imaging that supports timely interventions.
South Atlantic Nuclear Medicine Market held a 19.4% share in 2024. Increased investment in healthcare infrastructure in this zone, especially in states such as Georgia and Florida, has expanded patient access to nuclear diagnostics. Improvements in radiopharmaceutical efficacy and imaging hardware have also contributed to wider adoption across both hospitals and outpatient clinics in this area.
Key players shaping the U.S. Nuclear Medicine Market include Sirtex, GE Healthcare, Theragenics, Cardinal Health, RadioMedix, Lantheus, Curium Pharma, Novartis, Sun Pharma, Siemens Healthineers, Jubilant Pharma, RLS Radiopharmacies, Boston Scientific, Bracco, and Actinium Pharmaceuticals. To maintain a competitive edge in the U.S. Nuclear Medicine companies are prioritizing innovation in radiopharmaceutical development and strengthening their production and distribution networks. Many are investing in theranostic capabilities, targeting cancer and rare diseases with dual-function agents that offer both diagnosis and treatment. Strategic mergers, partnerships with diagnostic centers, and collaborations with academic institutions are common to accelerate clinical research and expand product pipelines. Additionally, manufacturers are enhancing supply chain efficiency by setting up regional radiopharmacies for faster delivery. Companies are also focused on securing FDA approvals for new compounds and expanding indications of existing ones, ensuring strong market penetration. Integration of AI with nuclear imaging platforms is another tactic being explored to improve diagnostic accuracy and clinical outcomes.
This product will be delivered within 2-4 business days.
The robust growth is fueled by the rise of radiopharmaceutical innovations, increased incidence of chronic diseases, expanding use of personalized treatments, and supportive reimbursement frameworks. Nuclear medicine, a highly specialized area of medical imaging and therapy, utilizes radiopharmaceuticals to both diagnose and treat medical conditions. Unlike traditional imaging methods, nuclear techniques offer deeper molecular and functional insight into tissues and organs. As the healthcare industry moves toward precision care, nuclear imaging is gaining prominence for its ability to deliver accurate diagnostics and targeted therapies. The sector is also being shaped by technological breakthroughs, the surge of oncology theranostics, rising investment in drug development, and an expanding network of diagnostic facilities. Theranostics is accelerating adoption in cancer care by combining imaging and therapeutic solutions into one approach. This enables real-time tracking of targeted radiopharmaceuticals, improving therapeutic precision and minimizing adverse effects, especially in oncology cases.
The diagnostics segment held a 66.5% share in 2024, due to growing demand for early-stage disease detection. The rising burden of cancer, heart disease, and neurological disorders is prompting widespread use of imaging platforms like PET and SPECT. These technologies provide accurate and early detection of illness, allowing for more effective and personalized treatment plans. Their ability to identify disease before structural changes occur is driving broader clinical acceptance.
The cardiology segment is projected to register a CAGR of 14.6% through 2034. This growth is backed by the rising number of patients with cardiovascular conditions and the need for accurate diagnostic procedures. Nuclear imaging modalities are proving critical in evaluating cardiac health, guiding physicians with detailed functional imaging that supports timely interventions.
South Atlantic Nuclear Medicine Market held a 19.4% share in 2024. Increased investment in healthcare infrastructure in this zone, especially in states such as Georgia and Florida, has expanded patient access to nuclear diagnostics. Improvements in radiopharmaceutical efficacy and imaging hardware have also contributed to wider adoption across both hospitals and outpatient clinics in this area.
Key players shaping the U.S. Nuclear Medicine Market include Sirtex, GE Healthcare, Theragenics, Cardinal Health, RadioMedix, Lantheus, Curium Pharma, Novartis, Sun Pharma, Siemens Healthineers, Jubilant Pharma, RLS Radiopharmacies, Boston Scientific, Bracco, and Actinium Pharmaceuticals. To maintain a competitive edge in the U.S. Nuclear Medicine companies are prioritizing innovation in radiopharmaceutical development and strengthening their production and distribution networks. Many are investing in theranostic capabilities, targeting cancer and rare diseases with dual-function agents that offer both diagnosis and treatment. Strategic mergers, partnerships with diagnostic centers, and collaborations with academic institutions are common to accelerate clinical research and expand product pipelines. Additionally, manufacturers are enhancing supply chain efficiency by setting up regional radiopharmacies for faster delivery. Companies are also focused on securing FDA approvals for new compounds and expanding indications of existing ones, ensuring strong market penetration. Integration of AI with nuclear imaging platforms is another tactic being explored to improve diagnostic accuracy and clinical outcomes.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Zone, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this U.S. Nuclear Medicine market report include:- Actinium Pharmaceuticals
- Boston Scientific
- Bracco
- Cardinal Health
- Curium Pharma
- GE Healthcare
- Jubilant Pharma
- Lantheus
- Novartis
- RadioMedix
- RLS Radiopharmacies
- Siemens Healthineers
- Sirtex
- Sun Pharma
- Theragenics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 7.8 Billion |
| Forecasted Market Value ( USD | $ 30.7 Billion |
| Compound Annual Growth Rate | 14.4% |
| Regions Covered | United States |
| No. of Companies Mentioned | 16 |
